87 related articles for article (PubMed ID: 15175685)
1. An image worth a thousand lives?
Hammond LA; Cavanaugh SX; Thomas CR
Nat Biotechnol; 2004 Jun; 22(6):677-8. PubMed ID: 15175685
[No Abstract] [Full Text] [Related]
2. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Smith-Jones PM; Solit DB; Akhurst T; Afroze F; Rosen N; Larson SM
Nat Biotechnol; 2004 Jun; 22(6):701-6. PubMed ID: 15133471
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
4. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
5. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Neckers L
Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
[No Abstract] [Full Text] [Related]
7. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
8. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.
Shen Y; Xie Q; Norberg M; Sausville E; Vande Woude G; Wenkert D
Bioorg Med Chem; 2005 Aug; 13(16):4960-71. PubMed ID: 15978816
[TBL] [Abstract][Full Text] [Related]
10. Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases.
Sakagami M; Morrison P; Welch WJ
Cell Stress Chaperones; 1999 Mar; 4(1):19-28. PubMed ID: 10467105
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
12. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
15. Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.
Murphy PJ
Leukemia; 2005 May; 19(5):710-2. PubMed ID: 15759036
[No Abstract] [Full Text] [Related]
16. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
18. A modular platform for the rapid site-specific radiolabeling of proteins with 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2.
Gill HS; Tinianow JN; Ogasawara A; Flores JE; Vanderbilt AN; Raab H; Scheer JM; Vandlen R; Williams SP; Marik J
J Med Chem; 2009 Oct; 52(19):5816-25. PubMed ID: 19736996
[TBL] [Abstract][Full Text] [Related]
19. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
Workman P
Mol Cancer Ther; 2003 Feb; 2(2):131-8. PubMed ID: 12589030
[No Abstract] [Full Text] [Related]
20. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N
Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
